Table 4. Asthma medication use for latent class phenotypes.
| Early transient wheeze n (%) |
Current wheeze/ asthma n (%) |
Mild asthma n (%) |
Moderate asthma n (%) |
|
|---|---|---|---|---|
| Any current asthma medication | 4 (3.9) | 4 (11.1) | 37 (56.1) |
61 (81.3) RR 1.5 (1.1, 1.9)b |
| β2 short- acting medication more than twice in the last week | 2 (2.0) | 2 (5.6) | 10 (15.2) |
26 (35.6) RR 2.4 (1.2, 4.9)a |
| Any regular preventer medication in the last 12 months | 0 (0) | 0 (0) | 17 (28.8) |
29 (40.9) RR 1.6 (1.0, 2.5)a |
| Any periodic preventer medication in the last 12 months | 3 (3.0) | 5 (13.9) | 21 (36.8) |
38 (58.5) RR 1.7 (1.1, 2.5)b |
| Regular ICS medication in the last 12 months | 0 (0) | 0 (0) | 9 (15.8) | 13 (20.6) 1.8 (0.8, 3.7) |
| Periodic ICS medication in the last 12 months | 1 (1.0) | 4 (11.4) | 17 (29.8) |
30 (47.6) RR 1.7 (1.1, 2.7)a |
| Regular β2 ICS combination medication in the last 12 months | 0 (0) | 0 (0) | 11 (19.3) | 19 (28.8) RR 1.6 (0.8, 3.3) |
| Periodic β2 ICS combination medication in the last 12 months | 2 (2.0) | 2 (5.7) | 5 (8.8) | 8 (12.1) RR 1.6 (0.6, 4.4) |
| Regular β2 long-acting medication in the last 12 months | 0 (0) | 0 (0) | 2 (3.6) | 5 (8.6) RR 2.5 (0.6, 9.9) |
| Periodic β2 long-acting medication in the last 12 months | 2 (2.0) | 1 (2.9) | 7 (12.7) | 9 (15.5) RR 1.3 (0.5, 3.3) |
| Regular LTRA medication in the last 12 months | 0 (0) | 0 (0) | 6 (10.5) | 5 (8.2) RR 0.8 (0.2, 2.7) |
| Periodic LTRA medication in the last 12 months | 1 (1.0) | 0 (0) | 5 (8.8) | 4 (6.6) RR 0.7 (0.2, 3.3) |
| Systemic corticosteroid in the last 12 months | 1 (1.0) | 3 (8.8) | 3 (5.4) | 3 (5.2) R 1.0 (0.2, 4.6) |
a p <0.05,
b p< 0.001,
Relative risks (RR) and 95% confidence intervals shown for Moderate asthma versus Mild asthma.